Pharma Leads Global Innovation Momentum
For the fourth year in a row, the pharmaceutical industry ranks as the top innovator in the LexisNexis® Intellectual Property Solutions Innovation Momentum Report. Published by our partners, the 2025 report highlights companies with exceptional innovation momentum, measured through patents.
The latest edition, Innovation Momentum 2025: The Global Top 100, focuses on the companies shaping the future of science and technology.
What Makes This Report Different
Unlike rankings that focus on patent volume, this report uses the LexisNexis® PatentSight+™ Patent Asset Index. This trusted metric measures the quality, relevance, and growth of a company’s patent portfolio.
Instead of showing historic totals, it tracks progress over the past two years. This provides a real-time snapshot of who is gaining momentum in innovation.
How Innovation Momentum Is Measured
The methodology highlights innovators by looking at patent quality, not just quantity. It uses three key indicators:
- Technology Relevance – showing potential for future inventions
- Market Coverage – reflecting the scope of patent protection
- Competitive Impact – the overall strength of a patent portfolio
Larger companies need more high-quality patents to move the needle. Smaller players can stand out with fewer—but more impactful—patents.
This approach shines a light on both emerging specialists and global leaders making the biggest strides in innovation.
Artificial Intelligence in Pharmaceuticals
Artificial Intelligence (AI) is changing the game in drug development. It helps model new drugs, predict their characteristics, and speed up discovery. AI is also optimizing clinical trials, improving manufacturing, and supporting personalized medicine.
Examples like Folding@home and DeepMind’s AlphaFold show how AI can solve complex biological puzzles. Pharma leaders such as BioNTech, Regeneron, and Bristol-Myers Squibb are already applying AI to strengthen innovation and efficiency.
Pharma Leaders in Innovation Momentum 2025
The 2025 report spotlights pharmaceutical companies making the greatest impact with their patents. These include both established players and rising biotech specialists.
Highlighted Innovators:
- Acuitas Therapeutics – Vancouver-based biotech advancing nucleic acid therapies with LNP delivery. Featured in 2023, 2024, 2025 reports.
- Alnylam Pharmaceuticals – U.S. company pioneering RNAi therapeutics. Featured in 2023, 2024, 2025.
- Amgen – U.S. biopharma in general medicine, rare disease, inflammation, and oncology. Featured all four years.
- Arvinas – Developer of PROTAC protein degraders. Featured in 2022, 2023, 2025.
- BioNTech – German immunotherapy leader in mRNA innovation. Featured in 2024 and 2025.
- Bristol Myers Squibb – Global pharma leader across oncology, HIV/AIDS, and more. Featured all four years.
- CureVac – German biotech specializing in mRNA therapies. Featured all four years.
- Eli Lilly – U.S. pharma with a focus on cardiometabolic health, oncology, immunology, and neuroscience. Featured 2023–2025.
- Gilead Sciences – Innovator in HIV, hepatitis, oncology, and inflammation. Featured all four years.
- Incyte – U.S. pharma focused on hematology and oncology. Featured all four years.
- Johnson & Johnson – Global healthcare leader. Featured all four years.
- Moderna Therapeutics – U.S. pioneer in mRNA across infectious and autoimmune diseases. Featured all four years.
- Novartis – Swiss pharma giant in cardiovascular, immunology, and neuroscience. Featured all four years.
- Novocure – Swiss oncology firm using TTFields therapy. First featured in 2025.
- Pfizer – U.S. biopharma leader in medicines and vaccines. Featured all four years.
- Regeneron – U.S. biotech innovating across serious diseases. Featured all four years.
- Revolution Medicines – Targeting RAS-addicted cancers. Featured all four years.
- Sanofi – French pharma company active in multiple therapeutic areas. Featured all four years.
- Wave Life Sciences – Developer of RNA-based medicines. First featured in 2025.
Regulatory Services for Pharma
At LexisNexis Reed Tech, we know innovation must align with strict regulations. Our experts provide end-to-end regulatory services to help pharma companies stay compliant.
Our solutions include:
- SPL conversion and FDA submissions
- eDRL coordinator services
- eCTD publishing and lifecycle management
- Drug label research and analytics
- SingleSource™ for Drug Products Premium platform
- Regulatory consulting and U.S. Agent representation
We support pharmaceutical companies with precision, speed, and trust, so they can focus on innovation.
About LexisNexis Reed Tech
LexisNexis Reed Tech helps life sciences innovators turn complex data into actionable insights. Our platforms enable companies to manage product data and meet compliance deadlines.
Together with LexisNexis® Intellectual Property Solutions, we help innovators stay competitive and bring life-changing solutions to market.
Learn more at ReedTech.com.